News

The 48-week data showed that Cyltezo is equivalent, with no clinically meaningful differences in efficacy, safety and immunogenicity to Humira in people with moderately-to-severely active rheumatoid arthritis (RA),

Cellectis agreed with the FDA to the following main revisions to be implemented in Phase 1 UCART123 protocols to lift the hold: Decrease of the cohort dose level

The company has submitted marketing authorization application (MAA) to the EMA for Kymriah to treat children and young adults with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia

The buyer will pay Valeant a 6% royalty on worldwide sales of libido drug Addyi (flibanserin), beginning 18 months from the signing of the sale agreement. In August 2015, Valeant

Unichem’s India business comprises of a portfolio of more than 120 brands in India and Nepal, manufacturing plant at Sikkim catering to these markets and all the employees

The acquisition is in line with Celonic’s vision to strengthen its position as a premier global player in the high-growth CDMO market, with continued investment in strategic assets

A research in this regard was carried out by investigators at the Stanford University School of Medicine in California. The scientists say that the new treatment option can

These clinical data were presented today in an oral presentation at the 1st European ATTR Amyloidosis Meeting for Patients and Doctors being held November 2-3, 2017 in Paris,

Pursuant to the Sublicense Agreement, Xenetic granted to Baxalta the right to grant a nonexclusive sublicense to certain patents related to the Company’s PolyXenInpex technology that were previously